NCT03404817View on ClinicalTrials.gov

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions
Cocaine Use Disorder
Interventions
DRUG

Original formulation EMB-001

Single oral dose (720 mg metyrapone/24 mg oxazepam)

DRUG

New formulation EMB-001

Single oral dose (720 mg metyrapone/24 mg oxazepam)

Trial Locations (1)

90806

Collaborative Neuroscience Network, LLC, Long Beach

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Embera NeuroTherapeutics, Inc.

INDUSTRY